Dynavax Technologies Corporation
Dynavax Technologies — ICAAC 2011
15 slides from Dynavax Technologies's conference presentation, Sep 21, 2011
Slide 1: Safety and Immunogenicity of HEPLISAV vs Engerix-B in Adults 40 to 70
An Observer-Blinded, Randomized, Parallel-Group, Multi- Center Study Comparing the Safety and Immunogenicity of HEPLISAV to Licensed Vaccine (Engerix-B®) among Healthy Subjects 40 to 70 Years of Age Exhibit 99.2 Sunday, September 18, 2011 ICAAC Chicago, IL
Slide 2: Background: HBV in older adults
Background: HBV in older adults HBV Vaccination for adults is recommended for persons at increased risk of infection Current HBV vaccines are less immunogenic in healthy adults age 40+ (Averhoff, AJPrevMed, 1998) There has been no decrease in the rate of HBV infection in adults age 40-59 in the US f
Slide 3: Introduction: HBV Vaccine
Introduction: HBV Vaccine Current licensed Hepatitis B virus (HBV) vaccine Contains µg HBsAg adjuvanted with aluminum hydroxide Administered in 3 doses on a 0,1, 6 month schedule HBsAg+ISS (HEPLISAV) Contains a new class of adjuvant (1018 ISS) Toll-like Receptor 9 (TLR9) agonist 20 µg HBsAg mixed wi
Slide 4: TLRs that recognize nucleic acids
4 of these TLR recognize nucleic acids TLR Overview TLR3 TLR7 TLR8 TLR9 TLR1 TLR2 TLR4 TLR5 TLR6 TLR10 TLR2 ssRNA CpG DNA (ISS) dsRNA ssRNA Endosome Cytosol Diacyl lipopeptides Triacyl lipopeptides LPS Flagellin ? TIRAP MyD88 TIRAP MyD88 MyD88 TIRAP TRAM TRIF MyD88 MyD88 MyD88 MyD88 TRIF MyD88
Slide 5: Study Design
HBV-16: Study Design Healthy adults, 40 to 70 years of age Two doses of HEPLISAV (0, 4 weeks) + 1 dose placebo (24 weeks) compared to 3 doses of Engerix-B (0, 4, 24 weeks) Immunogenicity assessed by Ortho Vitros ECi assay Seroprotection defined as anti-HBsAg miU/ml Randomization – HEPLISAV to Engeri
Slide 6: HBV-16: Visit Schedule
Active Active Placebo HEPLISAV HBV-16: Visit Schedule Week 0 Week 4 Week 8 Week 12 Week 18 Week 24 Week 28 Week 36 Week 44 Week 52 Screen and Randomize Active Active Active Injection Period Follow-up Period ENGERIX-B Week 32
Slide 7: Objectives - Immunogenicity
HBV-16: Objectives - Immunogenicity Primary Demonstrate non-inferiority to Engerix-B at 8 weeks after the last injection (week 12 for HEPLISAV vs. week 32 for Engerix-B) Non-inferiority (week HEPLISAV vs. week Engerix-B) HEPLISAV will be considered non-inferior to Engerix-B if the lower limit of the
Slide 8: Seroprotection Rates (Primary Endpoint)
HBV-16: Seroprotection Rates (Primary Endpoint) 0% 25% 50% 75% 100% Baseline Weeks HEPLISAV Engerix-B Engerix-B Injections HEPLISAV Injections Non-inferiority Per-Protocol Population Primary Endpoint % Difference in SPR at 8 weeks after last active dose: 19.6% (95% CI 14.7%, 24.7%) (N=1123 for HEPLI
Slide 9: Anti-HBsAg Geometric Mean Concentration
HBV-16: Anti-HBsAg Geometric Mean Concentration 1000 Baseline Weeks HEPLISAV Engerix-B Engerix-B Injections HEPLISAV Injections Non-inferiority Per-Protocol Population
Slide 10: HBV-16 Anti-HBsAg GMC: HEPLISAV Lot Consistency
HBV-16 Anti-HBsAg Geometric Mean Concentration: HEPLISAV Lot Consistency (Primary Endpoint) 1000 Baseline Lot 8 Lot 9 Lot 10 Engerix-B HEPLISAV Engerix-B Primary Endpoint (N= 428 for Lot 8; 438 for Lot 9; 424 for Lot 10)
Slide 11: HBV-16: Ratio of GMCs for Lot Consistency
Upper bound Lower bound Consistency Criteria HBV-16: Ratio of GMCs for Lot Consistency Adjusted Ratios Lot 10/Lot 8 Lot 10/Lot 9 Lot 8/Lot 9
Slide 12: Results - Safety
HBV-16: Results - Safety Post Injection Reactions Incidence similar in HEPLISAV (51.0%) vs. Engerix (49.4%) Severe reactions were uncommon and slightly lower in HEPLISAV (2.8% vs. 4.2%) Pain was more frequent in HEPLISAV (34.8% vs. 31.8%) Systemic post immunization reactions were less frequent in HE
Slide 13: Results - Safety
HBV-16: Results - Safety SAEs 123 SAEs reported in 99 subjects – 3.4% of subjects in HEPLISAV vs. 4.8% in Engerix-B Most common was in SOC of Musculoskeletal and Connective Tissue (1.1% HEPLISAV vs. 1.0% Engerix-B) 1 SAE was considered by PI to be treatment related – bronchial hyper-reactivity after
Slide 14: Conclusions
HBV-16: Conclusions In healthy adults aged 40 to 70 years: HEPLISAV provided superior peak seroprotection with fewer doses than Engerix-B HEPLISAV provided earlier seroprotection compared to Engerix-B HEPLISAV provided superior duration of seroprotection with fewer doses than Engerix-B The clinical
Slide 15: The HBV-16 Study Team
The HBV-16 Study Team Site Principle Investigators Michael Kyle Joe Blumenau Matthew Davis Martin Kabongo Reinaldo Tirado-Bernardini Dennis O’Keefe Tami Helmer Donald Sislen Ben Lasko Nancy Campbell Lunde Canas William Jennings Stephan Sharp Duane Wombolt Randle Middleton Eric Ross Maureen Ziboh Eug